Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one! Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers ! Time Limited Offer: Welcome Gift for New Customers !
| Project item | Indications | Research phase | Cooperation demands |
| BDA202204 | “hard-to-treat” solid tumors (pancreatic, gastric, etc) | License-out or co-development | License-out or co-development |
Immobilized Human TROP-2 (88-274) Protein, His Tag (Cat. No. TR2-H52H6) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2 Protein,Mouse IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
The purity of Biotinylated Mouse TROP-2 Protein, Fc,Avitag (Cat. No. TR2-M82F3) is more than 90% and the molecular weight of this protein is around 120-145 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | GS-0132; IMMU-132; TROP-2-SN-38; IMMU0132 | Approved | Immunomedics Inc | 拓达维, Trodelvy | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Carcinoma, Ovarian Epithelial; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Brain metastases; Metastatic breast cancer; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Solid tumours; Pancreatic Neoplasms; Glioblastoma; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Liver Failure; Ovarian Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BL-M02D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms | Details | |
| BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| KJ-103 | KJ-103 | Phase 1 Clinical | Kisoji Biotechnology Inc | Rejection of renal transplantation; Solid tumours | Details |
| DAC-002 | JS-108; DAC-002 | Phase 1 Clinical | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms | Details | |
| BAT-8008 | BAT8008; BAT-8008 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| SHR-A1921 | SHR-A1921; SHRA1921 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms | Details |
| MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
| 重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
| FDA018 Antibody Drug Conjugate | FDA-018-ADC; FDA018-ADC | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Neoplasm Metastasis | Details |
| SKB-264 | MK-2870; SKB-264 | Phase 3 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Datopotamab deruxtecan | Dato-DXd; DS-1062a; DS-1062 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.
A-Z
